skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia

(3201) Views  (762) Full article downloads

Authors: R Lozano, MG Peralta Concha, A Montealegre, L de Leon, J Ortiz Villalba, et al

Published Date February 2007 Volume 2007:3(1) Pages 149 - 155
DOI: http://dx.doi.org/10.2147/TCRM.S

R Lozano1, MG Peralta Concha2, A Montealegre3, L de Leon3, J Ortiz Villalba4, HO Lee Esteban5, M Cromeyer6, JA Rivas García7, A Brossa8, G Lluberes8, E Izquierdo Sandí9, H Burgos Quirós10

1Grupo Ferrer Internacional, Avda. Diagonal 549, E-08029, Barcelona, Spain; 2Department of Gastroenterology, Hospital de la Policía Nacional del Perú, Lima, Perú; 3Gastroenterology and Internal Medicine, Hospital Chiriquí, David, República de Panamá; 4Center of Medical Specialties, Asunción del Paraguay, Paraguay; 5Gastroklinik, Guatemala; 6Hospital de Diagnóstico, San Salvador, El Salvador; 7Hospital Escuela, Tegucigalpa, Honduras; 8Clínica Abreu, Santo Domingo, República de Santo Domingo; 9Hospital Dr. Calderón Guardia, San Pedro, San José, Costa Rica; and 10Gastroenterology Clinic, San Juan de Tibás, San José, Costa Rica

Abstract: The objective of this study was to assess the effectiveness and safety of levosulpiride in patients with dysmotility-like functional dyspepsia including nonerosive reflux esophagitis in conditions of daily practice. The study was conducted as a prospective, open-label, multicenter design in 342 patients with dysmotility-like functional dyspepsia (n=279) and nonerosive reflux disease (n=63), who received levosulpiride 25 mg 3 times daily orally for 4 weeks. Individual symptoms (pain/discomfort, fullness, bloating, early satiety, pyrosis, regurgitation, and nausea/vomiting) and a global symptom score were assessed at 15, 30, and 60 days after starting treatment. Adverse events also were recorded. There were 151 men and 191 women (mean age 38.8 years) who referred dyspeptic symptoms for a mean of 10.2 (10.7) months. A total of 66.4% patients were treated with 75 mg/day levosulpiride and 33.6% with 50 mg/day. At the 15-day visit, a decrease greater than 50% in the global symptom score was observed. The frequency and intensity of individual symptoms showed a statistically significant decrease (p<0.001) at all visits compared with baseline. At the 30-day visit, all symptoms had almost disappeared, a trend that was maintained until the last visit. Treatment with levosulpiride was well tolerated and only 40 adverse events were recorded (galactorrhea 26.7%, somnolence 17.8%, fatigue 11.1%, headache 11.5%) and no patient had to abandon the study due to side effects. In conclusion, levosulpiride is an effective and safe drug in the treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease.

Keywords: (MeSH terms): sulpiride/administration & dosage, dyspepsia/drug therapy, levosulpiride, sulpiride/analogs & derivatives, administration oral, adult








Readers of this article also read: